AstraZeneca makes important lung cancer step

AstraZeneca has taken an important step for non-small cell lung cancer treatment.

The European Commission has authorised the use of Iressa for adults suffering from locally advanced or metastatic forms of the disease, who also have activating mutations of epidermal growth factor receptor-tyrosine (EGFR) kinase across all lines of therapy.

It works by inhibiting an enzyme, which results in the transmission of signals involved in the growth and spread of tumours being blocked.

Anders Ekblom, executive vice-president for development at the company, explained Iressa is the first targeted medication for lung cancer.

He commented: “For the first time, patients with EGFR mutation positive tumours will have a more effective and better tolerated alternative to chemotherapy as a first-line treatment.”

The firm will now work with pathology groups and clinicians across the continent to facilitate appropriate access to diagnostic testing.

Last month, AstraZeneca’s development partner Pozen submitted an application to the Food and Drug Administration for Vimovo (PN400) (enteric coated naproxen /esomeprazole magnesium) tablets.